U.S. pharma huge copyright scrapped two experimental weight loss capsules past yr—a after-each day tablet, lotiglipron, due to elevated liver enzymes along with a twice-day-to-day tablet, danuglipron, due to strong Unwanted effects—but CEO Albert Bourla has explained the company is d